Ochre Bio: Funding, Investors & Team (Oct 2026)
Ochre Bio develops genomic medicines to rejuvenate donors' livers before transplant, so that everyone who needs a new liver gets one. They use genomics to find and shut down over-active genes driving disease and then go directly to testing therapies in discarded donor livers that keep alive outside of the body. Ochre Bio is within the heart of Oxford’s biotech innovation hub. Their scientific roots can be traced back to over 15 years leading liver genomics research and experience in bringing advanced therapies to market.
Ochre Bio has raised $30.2M across 2 funding rounds on record, the most recent a Series A of $30.0M announced in Oct 2022.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Ochre Bio Company Profile and Key Stats
Latest funding round on record: Oct 2022.
Ochre Bio Funding Rounds
Ochre Bio raised $200k in an undisclosed round announced in Mar 2020.
2.6 years later, a Series A of $30.0M was announced in Oct 2022.
Ochre Bio Founders and Leadership Team
No contact details are on record for this team yet.
Ochre Bio Funding Compared to Other Biotechnology Startups
Ochre Bio's latest round of $30.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Ochre Bio in Biotechnology and Oxford
Companies Similar to Ochre Bio
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug…
The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical…
Argonaute RNA company research projects build on existing intellectual property.
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
Ochre Bio Funding FAQs
What does Ochre Bio do?
Ochre Bio develops genomic medicines to rejuvenate donors' livers before transplant, so that everyone who needs a new liver gets one. They use genomics to find and shut down over-active genes driving disease and then go directly to testing therapies in discarded donor livers that keep alive outside of the body. Ochre Bio is within the heart of Oxford’s biotech innovation hub. Their scientific roots can be traced back to over 15 years leading liver genomics research and experience in bringing advanced therapies to market.
How much funding has Ochre Bio raised?
Ochre Bio has raised $30.2M across 2 rounds on record. The most recent is a Series A of $30.0M announced in Oct 2022.
When did Ochre Bio last raise funding?
Ochre Bio's most recent funding round on record is a Series A of $30.0M, announced in Oct 2022.
Who is the CEO of Ochre Bio?
Jack O'meara is listed as CEO at Ochre Bio.
Where is Ochre Bio headquartered?
Ochre Bio is based in Oxford, Oxfordshire, United Kingdom.
How many employees does Ochre Bio have?
Ochre Bio is in the 11-50 employee band.
How does Ochre Bio's funding compare to other Biotechnology startups?
Ochre Bio's latest round of $30.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Ochre Bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Ochre Bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.